Nektar Therapeutics (NKTR) Income from Continuing Operations: 2009-2024
Historic Income from Continuing Operations for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to -$119.0 million.
- Nektar Therapeutics' Income from Continuing Operations rose 5.58% to -$35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.4 million, marking a year-over-year increase of 32.63%. This contributed to the annual value of -$119.0 million for FY2024, which is 56.90% up from last year.
- Nektar Therapeutics' Income from Continuing Operations amounted to -$119.0 million in FY2024, which was up 56.90% from -$276.1 million recorded in FY2023.
- In the past 5 years, Nektar Therapeutics' Income from Continuing Operations registered a high of -$119.0 million during FY2024, and its lowest value of -$525.1 million during FY2021.
- In the last 3 years, Nektar Therapeutics' Income from Continuing Operations had a median value of -$276.1 million in 2023 and averaged -$256.7 million.
- Per our database at Business Quant, Nektar Therapeutics' Income from Continuing Operations dropped by 18.15% in 2021 and then surged by 56.90% in 2024.
- Yearly analysis of 5 years shows Nektar Therapeutics' Income from Continuing Operations stood at -$444.4 million in 2020, then decreased by 18.15% to -$525.1 million in 2021, then increased by 28.56% to -$375.1 million in 2022, then rose by 26.41% to -$276.1 million in 2023, then spiked by 56.90% to -$119.0 million in 2024.